TY - JOUR
T1 - Hepatic steatosis in patients with schizophrenia
T2 - a clinical cross-sectional study
AU - Aarøe, Anna Sofie Kaestel
AU - Odgaard Maeng, Katrine
AU - Leifsdottir Jacobsen, Ragnhild
AU - Eggert Jensen, Svend
AU - Graff, Claus
AU - Polcwiartek, Christoffer
AU - Bolvig Mark, Esben
AU - Dalsgaard, Anja Borgen
AU - Tranekaer Hostrup, Camilla
AU - Veiss-Pedersen, Pernille
AU - Frøkjaer, Jens Brøndum
AU - Aagaard, Jørgen
AU - Nielsen, René Ernst
PY - 2022
Y1 - 2022
N2 - OBJECTIVE: With hepatic steatosis (HS) being an established risk factor for CVD in the general population, it may also be a predictor of CVD in patients with schizophrenia. The aim of the present study was to investigate if time since schizophrenia diagnosis, body mass index (BMI), sex, metabolic syndrome, alcohol use, smoking, alanine transaminase (ALT), and body fat percentage (as measured by bioelectrical impedance) were associated with HS, determined by computed tomography (CT), in a population of patients diagnosed with schizophrenia.METHODS: Moderate to severe HS (40 CT Hounsfield units as threshold) was determined utilizing non-contrast enhanced CT. The association between the explanatory variables and outcome of HS was assessed using multivariable logistic regression.RESULTS: In the present study, 145 patients diagnosed with schizophrenia (mean age 42.2 years (SD ± 13.8)) were included, with 88 (60.7%) being male. On average, patients had been diagnosed for 14.8 (SD ± 10.7) years. A total of 31 (21.4%) patients had HS as determined by CT. The presence of HS was associated with ALT (OR 1.06, 95% CI (1.02-1.10) per 1 U/L increase), and the presence of metabolic syndrome (OR 62.89, 95% CI (2.03-1949.55)). The presence of HS was not associated with BMI, body fat percentage or time since diagnosis in the multivariable analysis.CONCLUSION: Higher ALT and the presence of metabolic syndrome were associated with HS in patients with schizophrenia utilizing multivariable analysis. The findings suggest that risk factors for HS are similar in both the general population and in patients with schizophrenia.
AB - OBJECTIVE: With hepatic steatosis (HS) being an established risk factor for CVD in the general population, it may also be a predictor of CVD in patients with schizophrenia. The aim of the present study was to investigate if time since schizophrenia diagnosis, body mass index (BMI), sex, metabolic syndrome, alcohol use, smoking, alanine transaminase (ALT), and body fat percentage (as measured by bioelectrical impedance) were associated with HS, determined by computed tomography (CT), in a population of patients diagnosed with schizophrenia.METHODS: Moderate to severe HS (40 CT Hounsfield units as threshold) was determined utilizing non-contrast enhanced CT. The association between the explanatory variables and outcome of HS was assessed using multivariable logistic regression.RESULTS: In the present study, 145 patients diagnosed with schizophrenia (mean age 42.2 years (SD ± 13.8)) were included, with 88 (60.7%) being male. On average, patients had been diagnosed for 14.8 (SD ± 10.7) years. A total of 31 (21.4%) patients had HS as determined by CT. The presence of HS was associated with ALT (OR 1.06, 95% CI (1.02-1.10) per 1 U/L increase), and the presence of metabolic syndrome (OR 62.89, 95% CI (2.03-1949.55)). The presence of HS was not associated with BMI, body fat percentage or time since diagnosis in the multivariable analysis.CONCLUSION: Higher ALT and the presence of metabolic syndrome were associated with HS in patients with schizophrenia utilizing multivariable analysis. The findings suggest that risk factors for HS are similar in both the general population and in patients with schizophrenia.
KW - Fatty liver disease
KW - cardiovascular disease
KW - computed tomography
KW - hepatic steatosis
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85111459635&partnerID=8YFLogxK
U2 - 10.1080/08039488.2021.1939779
DO - 10.1080/08039488.2021.1939779
M3 - Journal article
C2 - 34289326
SN - 0803-9488
VL - 76
SP - 114
EP - 119
JO - Nordic Journal of Psychiatry
JF - Nordic Journal of Psychiatry
IS - 2
ER -